Loading patent…
OwnerDavid I. Coheninventor
Estimating the term…
Anti-lentivirus vaccines and immunotherapeutics and methods for preparing and using same are disclosed. The vaccines and immunotherapeutics are produced using non-immunosuppressive lentivirus trans-activator of transcription (Tat) proteins. An associated in vitro ultra-sensitive macrophage Tat bioassay is disclosed for assessing the immunosuppressive qualities of the lentivirus Tat preparations of the present invention. Additionally, a related long-term T4 cell propagation system for characterizing lentivirus Tat is also disclosed. The present invention has additional utility in the treatment and prevention of AIDS.
A lentivirus vaccine comprising:
A lentivirus immunotherapeutic comprising:
A vaccine adjuvant comprising non-immunosuppressant lentivirus trans-activator (Tat) protein.
A treatment for lentivirus diseases comprising administering a non-immunosuppressant lentivirus trans-activator (Tat) protein to a lentivirus infected mammal.
The treatment for lentivirus diseases of claim 15 wherein said lentivirus disease is HIV disease.
An in vitro ultra-sensitive macrophage Tat bioassay comprising:
A long-term T4 cell propagation system comprising:
A method for characterizing lentivirus Tat comprising the steps, of;
Dependencies are inferred from the claim text.